30 April 2024
Clifford Chance advises ESTEVE on its binding offer for the acquisition of HRA Pharma Rare Diseases
Advising firms
Deal team
13 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Guillermo Guardia Lead | Clifford Chance | Partner | Corporate / M&A | Not stated |
| Jose Maria Vilaseca | Clifford Chance | Senior associate | Not stated | Not stated |
| Estel Casas | Clifford Chance | Associate | Not stated | Not stated |
| María Viñas | Clifford Chance | Associate | Not stated | Not stated |
| Alex Jori | Clifford Chance | Associate | Not stated | Not stated |
| Fernando Escribano | Clifford Chance | Counsel | tax | Not stated |
| Jorge Martín-Fernández | Clifford Chance | Counsel | employment | Not stated |
| Marianne Pezant | Clifford Chance | Partner | Not stated | Paris |
| Thomas Krecek | Clifford Chance | Partner | Not stated | Frankfurt |
| Gareth Camp | Clifford Chance | Partner | Not stated | London |
| Thais Garcia | Clifford Chance | Partner | Not stated | New York |
| Umberto Penco Salvi | Clifford Chance | Partner | Not stated | Milan |
| Niek De Pauw | Clifford Chance | Partner | Not stated | Brussels |
Stated terms
- Stated value
- EUR 275m (EUR 275 million)
- What the figure measures
- Total transaction value
- Client
- ESTEVEBuy-side
- Counterparties
- Perrigo Company (Sell-side)